Differential roles of phosphoinositide-dependent protein kinase-1 and akt1 expression and phosphorylation in breast cancer cell resistance to Paclitaxel, Doxorubicin, and gemcitabine - PubMed (original) (raw)
. 2006 Sep;70(3):1045-52.
doi: 10.1124/mol.106.023333. Epub 2006 Jun 16.
Affiliations
- PMID: 16782806
- DOI: 10.1124/mol.106.023333
Differential roles of phosphoinositide-dependent protein kinase-1 and akt1 expression and phosphorylation in breast cancer cell resistance to Paclitaxel, Doxorubicin, and gemcitabine
Ke Liang et al. Mol Pharmacol. 2006 Sep.
Abstract
3-Phosphoinositide-dependent protein kinase-1 (PDK1) and Akt1 are two closely related components of the phosphatidylinositol-3 kinase (PI3K) pathway, which is aberrantly regulated in breast cancer. Despite the importance of PDK1, few studies have evaluated it as a potential target for cancer therapy compared with studies of Akt1. We hypothesized that PDK1 is a superior target in the PI3K pathway. To test this, we first used a mouse mammary cell line retrovirally infected to express human PDK1 or Akt1 for comparative studies of treatment with paclitaxel, doxorubicin, and gemcitabine. Overexpression of PDK1 or Akt1 conferred similar resistance to treatment with paclitaxel or doxorubicin compared with control cells. However, the PDK1-overexpressing cells were more resistant to gemcitabine than were the Akt1-overexpressing cells. We next correlated the expression and activation-specific phosphorylation of PDK1 and Akt1 with the cytotoxic effects of the same agents in several human breast cancer cell lines. Cells with high levels of phosphorylated PDK1 were more resistant to gemcitabine-induced apoptosis than cells expressing high levels of phosphorylated Akt1. To further validate this observation, we used small interfering RNA oligonucleotides to selectively knock down PDK1 or Akt1 expression in MCF7 human breast cancer cells. We found that knockdown of PDK1 expression sensitized MCF7 cells to gemcitabine-induced apoptosis more effectively than did knockdown of Akt1 expression in the same cells. Our findings show that PDK1 may be a superior alternative to Akt1 as a target for sensitizing breast cancer cells to chemotherapeutic agents, particularly gemcitabine.
Similar articles
- Akt1 sequentially phosphorylates p27kip1 within a conserved but non-canonical region.
Nacusi LP, Sheaff RJ. Nacusi LP, et al. Cell Div. 2006 Jun 16;1:11. doi: 10.1186/1747-1028-1-11. Cell Div. 2006. PMID: 16780593 Free PMC article. - Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling.
Elwenspoek MM, Thom H, Sheppard AL, Keeney E, O'Donnell R, Jackson J, Roadevin C, Dawson S, Lane D, Stubbs J, Everitt H, Watson JC, Hay AD, Gillett P, Robins G, Jones HE, Mallett S, Whiting PF. Elwenspoek MM, et al. Health Technol Assess. 2022 Oct;26(44):1-310. doi: 10.3310/ZUCE8371. Health Technol Assess. 2022. PMID: 36321689 Free PMC article. - Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M, Chen CS. Tseng PH, et al. Mol Pharmacol. 2006 Nov;70(5):1534-41. doi: 10.1124/mol.106.023911. Epub 2006 Aug 3. Mol Pharmacol. 2006. PMID: 16887935 - Chemotherapy and radiotherapy for advanced pancreatic cancer.
Chin V, Nagrial A, Sjoquist K, O'Connor CA, Chantrill L, Biankin AV, Scholten RJ, Yip D. Chin V, et al. Cochrane Database Syst Rev. 2018 Mar 20;3(3):CD011044. doi: 10.1002/14651858.CD011044.pub2. Cochrane Database Syst Rev. 2018. PMID: 29557103 Free PMC article. Updated. Review. - Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
Bryant A, Hiu S, Kunonga PT, Gajjar K, Craig D, Vale L, Winter-Roach BA, Elattar A, Naik R. Bryant A, et al. Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2. Cochrane Database Syst Rev. 2022. PMID: 36161421 Free PMC article. Review.
Cited by
- PPARδ activation acts cooperatively with 3-phosphoinositide-dependent protein kinase-1 to enhance mammary tumorigenesis.
Pollock CB, Yin Y, Yuan H, Zeng X, King S, Li X, Kopelovich L, Albanese C, Glazer RI. Pollock CB, et al. PLoS One. 2011 Jan 13;6(1):e16215. doi: 10.1371/journal.pone.0016215. PLoS One. 2011. PMID: 21297860 Free PMC article. - Cancer development, progression, and therapy: an epigenetic overview.
Sarkar S, Horn G, Moulton K, Oza A, Byler S, Kokolus S, Longacre M. Sarkar S, et al. Int J Mol Sci. 2013 Oct 21;14(10):21087-113. doi: 10.3390/ijms141021087. Int J Mol Sci. 2013. PMID: 24152442 Free PMC article. Review. - Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer.
Yang J, Xu J, Zhang B, Tan Z, Meng Q, Hua J, Liu J, Wang W, Shi S, Yu X, Liang C. Yang J, et al. Int J Mol Sci. 2021 Oct 10;22(20):10944. doi: 10.3390/ijms222010944. Int J Mol Sci. 2021. PMID: 34681603 Free PMC article. Review. - Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells.
Hu Y, Guo R, Wei J, Zhou Y, Ji W, Liu J, Zhi X, Zhang J. Hu Y, et al. Cell Death Dis. 2015 Dec 17;6(12):e2020. doi: 10.1038/cddis.2015.363. Cell Death Dis. 2015. PMID: 26673665 Free PMC article. - AKT Isoforms as a Target in Cancer and Immunotherapy.
Smit DJ, Jücker M. Smit DJ, et al. Curr Top Microbiol Immunol. 2022;436:409-436. doi: 10.1007/978-3-031-06566-8_18. Curr Top Microbiol Immunol. 2022. PMID: 36243855
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous